Media Centre
Latest press releases
-
Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial in 1st-line unresectable liver cancer
-
AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial
-
Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis
-
AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US
-
Enhertu granted Breakthrough Therapy Designation in US for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 (0)1223 344 800
Kim Blomley
Director, Global Media Relations (Corporate)
+44 (0)1223 344 800
Angela Fiorin
Director, Global Media Relations (BioPharmaceuticals)
+44 (0)1223 344 800
Chris Calland
Director, Global Media Relations (Oncology)
+44 (0)1223 344 800
Fiona Cookson
Director, Global Media Relations
(COVID-19 vaccine)
+44 (0)1223 344 800
Sinead Keller
Director, Global Media Relations
(COVID-19 vaccine)
+44 (0)1223 344 800
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
Holly Campbell
Head, US Corporate Communications
+1 302 885 2677
Lisa Taylor
Senior Director, Corporate Communications (Alexion)
+1 857 338 9025
Amanda Talamonte
Manager, Global Media Relations
+44 (0)1223 344 800
Flavia Garcia
Manager, Global Media Relations
+44 (0)1223 344 800
